Evidence map›Paper›PMID 32691370›Full record

ArticleStem cell reviews and reports2021

SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45

Mariusz Z Ratajczak, Kamila Bujko, Andrzej Ciechanowicz, Kasia Sielatycka, Monika Cymer, Wojciech Marlicz, Magda Kucia

Open access · hybridAbstract read
In one paragraph

Article in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome.International journal of cardiology. Heart & vasculature · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. A20 as a Potential Therapeutic Target for COVID-19.Immunity, inflammation and disease · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mariusz Z RatajczakStem Cell Institute at James Graham Brown Cancer Center, University of Louisville, 500 S. Floyd Street, Rm. 107, Louisville, KY, 40202, USA. mzrata01@louisville.edu.ORCID 0000-0002-0071-0198
Kamila BujkoStem Cell Institute at James Graham Brown Cancer Center, University of Louisville, 500 S. Floyd Street, Rm. 107, Louisville, KY, 40202, USA.
Andrzej CiechanowiczDepartment of Regenerative Medicine, Center for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.
Kasia SielatyckaInstitute of Biology, Faculty of Exact and Natural Sciences, University of Szczecin, Szczecin, Poland.
Monika CymerDepartment of Regenerative Medicine, Center for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.
Wojciech MarliczResearch and Developmental Center Sanprobi, Szczecin, Poland.
Magda KuciaStem Cell Institute at James Graham Brown Cancer Center, University of Louisville, 500 S. Floyd Street, Rm. 107, Louisville, KY, 40202, USA. mjkuci01@louisville.edu.
University of Louisville · USMedical University of Warsaw · PLUniversity of Szczecin · PL

Funding

NIH HHS 2R01 DK074720
6 · The paper itself

Abstract

Angiotensin-converting enzyme 2 (ACE2) plays an important role as a member of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II (Ang II) into angiotensin (1-7) (Ang [1-7]). But at the same time, while expressed on the surface of human cells, ACE2 is the entry receptor for SARS-CoV-2. Expression of this receptor has been described in several types of cells, including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which raises a concern that the virus may infect and damage the stem cell compartment. We demonstrate for the first time that ACE2 and the entry-facilitating transmembrane protease TMPRSS2 are expressed on very small CD133

Indexed as

Angiotensin-Converting Enzyme 2AnimalsCOVID-19Endothelial CellsHematopoietic Stem CellsHumansInflammasomesLeukocyte Common AntigensNLR Family, Pyrin Domain-Containing 3 ProteinSARS-CoV-2Serine EndopeptidasesSpike Glycoprotein, CoronavirusVirus InternalizationACE2 protein, humanAngiotensin-Converting Enzyme 2InflammasomesLeukocyte Common AntigensNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanSerine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TMPRSS2 protein, humanACE2COVID19Cytokine stormHematopoietic stem cellsNlrp3 inflammasomePyroptosisSARS-CoV-2Spike proteinVSELs

Identifiers

PMID32691370
PMCPMC7370872
OpenAlexW3043697210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.